Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
10.01
-2.16 (-17.75%)
At close: May 30, 2025, 4:00 PM
10.22
+0.21 (2.05%)
After-hours: May 30, 2025, 7:42 PM EDT

Maze Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Revenue
167.5167.5--
Gross Profit
167.5167.5--
Selling, General & Admin
28.126.4224.6122.83
Research & Development
89.283.573.9588.19
Operating Expenses
117.3109.9198.55111.03
Operating Income
50.257.59-98.55-111.03
Interest & Investment Income
6.994.651.972.03
Earnings From Equity Investments
----3.54
EBT Excluding Unusual Items
57.1962.24-96.59-112.54
Gain (Loss) on Sale of Investments
----2.4
Other Unusual Items
-4.08-8.84-3.83-
Pretax Income
53.1153.4-100.42-114.94
Income Tax Expense
1.171.17--
Net Income
51.9452.23-100.42-114.94
Preferred Dividends & Other Adjustments
48.8348.83--
Net Income to Common
3.113.41-100.42-114.94
Shares Outstanding (Basic)
9222
Shares Outstanding (Diluted)
9322
Shares Change (YoY)
303.36%19.33%13.82%-
EPS (Basic)
0.351.42-43.89-57.18
EPS (Diluted)
0.341.25-43.89-57.18
Free Cash Flow
68.7174.81-87.27-101.17
Free Cash Flow Per Share
7.3827.40-38.14-50.33
Gross Margin
100.00%100.00%--
Operating Margin
29.97%34.38%--
Profit Margin
1.86%2.03%--
Free Cash Flow Margin
41.02%44.66%--
EBITDA
53.2360.88-94.46-107.21
EBITDA Margin
31.78%36.35%--
D&A For EBITDA
3.033.34.093.82
EBIT
50.257.59-98.55-111.03
EBIT Margin
29.97%34.38%--
Effective Tax Rate
2.21%2.20%--
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q